← Back to all recalls
DRUG RECALLMODERATE
Erythromycin Tablets 250 mg
Zydus recalls Erythromycin 250 mg tablets due to impurity above acceptable limit.
What to do
Consumers should stop using the recalled tablets and return them to the place of purchase or contact Zydus Pharmaceuticals for a refund or replacement.
Why it was recalled
Zydus Pharmaceuticals is recalling Erythromycin Tablets, USP, 250 mg, due to CGMP deviations and the presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit.
Is mine affected?
Check the NDC or UPC and strength printed on the package. Yours is affected if it matches one below.
Erythromycin Tablets, USP
| Lot code | Strength | NDC / UPC | Recall # |
|---|---|---|---|
| M411147, 2026 | 500 mg | NDC 70710-1048-3 | D-0545-2026 |
| M411146, 2026 | 250 mg | NDC 70710-1047-3, NDC 70710-1047-1 | D-0544-2026 |
Where it was sold
Distributed nationwide.
Timeline
- Firm initiated recall
- Publicly announced
- Listed on Recall Canary
- Summary updated
Official source
Other recent recalls from Zydus Pharmaceuticals (USA) Inc
Editorial summary by Recall Canary · summary updated 2026-09-03 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification